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Introduction
The success of HIV treatment is limited by tolerability/
toxicity of ARVs and patient adherence remains para-
mount to achieve viral suppression. Several small studies
have investigated the combination Raltegravir and Ata-
zanavir. This is particularly attractive to exclude NRTIs
and ritonavir in metabolic toxicity. Optimum dosing has
yet to be decided however recent data from SPARTAN
suggests once daily regimens are associated with ralte-
gravir resistance.
Objectives
To assess HIV virologic control in patients switched to
RAL/ATZ. To compare metabolic parameters before
and after switch.
Methods
We retrospectively identified patients RAL/ATZ from
pharmacy database. Using medical notes and lab results
system, we recorded the HIV-1 VL and lipid profiles
pre- and post- switch. TDM, hepatitis status, drug resis-
tance and treatment experience were also recorded.
Results
We identified 11 patients on RAL/ATZ, 9 male. At
switch, 1 patient had a detectable VL (582 copies/mL),
all other patients were undetectable. At the most recent
appointment all patients had an undetectable viral load.
The mean number of previous regimens was 5; no
patient commenced the regimen with known PI resis-
tance. In 5 patients other ARVs were included, and in 6
RAL/ATZ were used alone.
Therapeutic drug levels of raltegravir and atazanavir
were measured in 9/11 patients and the predicted
trough levels for both raltegravir and atazanavir were
greater than the minimum recommended concentration.
There was a reduction in total cholesterol and triglycer-
ides post switch and a trend towards reduction in LDL-
cholesterol and total cholesterol:HDL ratio. Two
patients were lost to follow up and three patients dis-
continued the combination. The reasons for disconti-
nuation: to avoid drug interactions pre-renal transplant,
to aid adherence (once daily regimen) and presumed ral-
tegravir intolerance (anxiety and sleep disturbance).
Conclusions
A switch was made when 10/11 patients were sup-
pressed and required therapy change because of another
reason. All patients maintained a viral load of less than
50 copies/ml (7-102 weeks).The combination was well
tolerated and there was a trend towards improved lipid
parameters observed. In the absence of resistance, this
combination shows promise in terms of prolonged viro-
logic efficacy, tolerability and an improved metabolic
profile.
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